Soy extract is a broad product description. To evaluate a claim about genistein and prostate cancer, identify the preparation studied, the people who received it, the comparison group, and the outcome measured. Soy foods, isolated protein, and concentrated isoflavone extracts answer different research questions.
Pin down what “soy” means
Tofu, tempeh, edamame, and soy milk are foods. Supplements may contain soy protein, isoflavones, or other fractions. Genistein is one isoflavone; the amount in a concentrated extract can differ markedly from the amount in a food portion. NCCIH’s soy fact sheet explains these product differences and why results can vary across preparations and populations.
A label saying “500 mg soy extract” may describe the extract’s total weight. Find any separate declaration of isoflavones or genistein, and the number of capsules per serving. A product with the same plant name as a trial preparation may still have a different composition.
Read the research in its clinical setting
On a narrow screen, scroll the table sideways. Keyboard users can focus the table region and use the arrow keys.
| Study | Design and question | Useful interpretation |
|---|---|---|
| deVere White and colleagues, 2004 | Six-month, open-label pilot enrolling 62 men with prostate cancer and elevated PSA; tested a genistein-rich extract. | An exploratory study of a biomarker in diagnosed patients. Its design cannot establish cancer prevention in healthy people. |
| Bosland and colleagues, 2013 | Randomized, blinded trial of 177 men at high recurrence risk after prostate removal; soy protein isolate compared with a casein-based control for up to two years. | Soy supplementation did not reduce biochemical recurrence in that setting. The study does not answer every question about ordinary soy foods. |
In the 2004 pilot, 52 of the 62 enrolled men were evaluable at six months. One met the planned outcome of a PSA reduction greater than 50%; seven others had smaller declines. This shows why the largest individual response is an incomplete summary. The 2013 trial found biochemical recurrence in 27.2% of the evaluated soy group and 29.5% of the control group, a difference that did not establish benefit.
The National Cancer Institute’s evidence review describes laboratory findings and observational associations that motivated this research. It also explains that early clinical trials have varied in population, dose, and design and have not established reduced prostate-cancer progression. Soy has no FDA approval as a cancer treatment.
These distinctions matter when a headline compresses a research program into “prevents cancer.” A study enrolling people who already have cancer starts with a treatment or disease-monitoring question. Demonstrating prevention would require an appropriate population and an outcome measuring new disease.
Keep the outcome attached to the number
PSA is a blood biomarker used in prostate care. Its interpretation depends on the person’s history and treatment. A percentage decline in PSA describes a change in that measured quantity; by itself it does not tell you whether someone lives longer, avoids progression, or feels better. Read what the study actually counted.
Look beyond the largest response reported. Find the planned primary outcome, the total number enrolled, the number analyzed, and the uncertainty around the estimate. An analysis restricted to people who completed a study may tell a different story from one that accounts for everyone who started.
Use a five-field note when reading a claim: product; population; comparison; outcome; duration. If an advertisement omits one field, follow its study link. If the study cannot be identified, the claim remains difficult to evaluate.
Bring the product and the question to your care team
Before starting a concentrated supplement during cancer care, show your oncologist or pharmacist the complete label and medication list. NCCIH reports gastrointestinal side effects and medication-interaction concerns for some soy products. Soy allergy also matters. A record of short-term tolerability in a trial leaves questions about a different product, longer use, and your treatment combination.
- What result am I hoping for, and has this exact kind of product demonstrated it?
- Does the cited study involve my stage of disease and treatment setting?
- Could this supplement interfere with treatment, medicines, or interpretation of monitoring?
- Would an oncology dietitian help with appetite, protein intake, or ordinary soy foods?
- What is the follow-up plan for any concern that led me to consider the supplement?
Continue prescribed cancer care and monitoring. Describe the preparation and dose explicitly so your team can assess the actual product and intended use.
For another example of distinguishing a food nutrient from a medical intervention, see vitamin C and cancer research. For everyday food planning, explore the nutrition library.